Global Short Bowel Syndrome (SBS) Market to Reach $5.7 Billion by 2030
The global market for Short Bowel Syndrome (SBS) estimated at US$1.2 Billion in the year 2022, is projected to reach a revised size of US$5.7 Billion by 2030, growing at a CAGR of 21.6% over the analysis period 2022-2030. GLP-2, one of the segments analyzed in the report, is projected to record 23.3% CAGR and reach US$4.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Growth Hormone segment is readjusted to a revised 21.1% CAGR for the next 8-year period.The U.S. Market is Estimated at $355.4 Million, While China is Forecast to Grow at 20.3% CAGR
The Short Bowel Syndrome (SBS) market in the U.S. is estimated at US$355.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$934.2 Million by the year 2030 trailing a CAGR of 20.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 19.3% and 18% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR.Select Competitors (Total 42 Featured) -
- Ardelyx, Inc.
- Emmaus Life Sciences, Inc.
- Merck KgaA
- Naia Pharmaceuticals Inc.
- Nutrien Ltd.
- OxThera AB
- Shire PLC
- Zealand Pharma A/S
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Short Bowel Syndrome (SBS) - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Short Bowel Syndrome (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Short Bowel Syndrome (SBS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for GLP-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for GLP-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for GLP-2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Growth Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Glutamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Glutamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Glutamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 16: World Short Bowel Syndrome (SBS) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- Table 17: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 23: USA Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 24: USA Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 25: USA 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 26: USA Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: USA Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 28: USA 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- CANADA
- Table 29: Canada Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 30: Canada Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 31: Canada 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 32: Canada Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: Canada Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 34: Canada 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- JAPAN
- Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 35: Japan Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 36: Japan Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 37: Japan 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 38: Japan Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 39: Japan Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 40: Japan 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- CHINA
- Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 41: China Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 42: China Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 43: China 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 44: China Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: China Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 46: China 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- EUROPE
- Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 47: Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 48: Europe Historic Review for Short Bowel Syndrome (SBS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 49: Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 52: Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- FRANCE
- Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 56: France Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 57: France Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 58: France 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 59: France Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 60: France Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 61: France 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- GERMANY
- Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 62: Germany Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 63: Germany Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 64: Germany 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 65: Germany Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 66: Germany Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 67: Germany 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- ITALY
- Table 68: Italy Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 69: Italy Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 70: Italy 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 71: Italy Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 72: Italy Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 73: Italy 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 74: UK Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 75: UK Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 76: UK 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 77: UK Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 78: UK Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 79: UK 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 80: Rest of Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 81: Rest of Europe Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 82: Rest of Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 83: Rest of Europe Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 84: Rest of Europe Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 85: Rest of Europe 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Short Bowel Syndrome (SBS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 87: Asia-Pacific Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 88: Asia-Pacific 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 90: Asia-Pacific Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 91: Asia-Pacific 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 92: Rest of World Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of World Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 94: Rest of World 16-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 95: Rest of World Recent Past, Current & Future Analysis for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 96: Rest of World Historic Review for Short Bowel Syndrome (SBS) by Mode of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 97: Rest of World 16-Year Perspective for Short Bowel Syndrome (SBS) by Mode of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ardelyx, Inc.
- Emmaus Life Sciences, Inc.
- Merck KgaA
- Naia Pharmaceuticals Inc.
- Nutrien Ltd.
- OxThera AB
- Shire PLC
- Zealand Pharma A/S
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 194 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 1.2 Billion |
Forecasted Market Value ( USD | $ 5.7 Billion |
Compound Annual Growth Rate | 21.5% |
Regions Covered | Global |